Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199000 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL1085064 | 0.88 | POLB (0.47) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL8260078 | 0.86 | POLB (0.49) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL24069435 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL11607443 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL15525073 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL29384281 | 0.81 | ALDH1A1 (0.74) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL473877 | 0.81 | ALDH1A1 (0.74) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL7398287 | 0.79 | POLB (0.53) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL2132960 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025134150-A1 | BIPHENYL PYRIDINE RIGID COMPOUNDS WITH POLYCYCLIC HETEROCYCLES USEFUL AS DUAL IMMUNE CHECKPOINT INHIBITORS | NATCO PHARMA LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-06-05 | — | — | US | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| CN-111886219-B | Immunosuppressant, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2020011209-A1 | IMMUNOSUPPRESSIVE AGENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2020-01-16 | — | — | WO | disclosed |
| EP-3318556-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-2630123-B1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9278103-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9168259-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-8552200-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2630123-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052167-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | KCNQ2, KCNQ1, KCNQ3 | ALDH1A1 2214/4885MAPK1 1908/4885SMN1; SMN2 808/4885 |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | ALDH1A1 2214/4885MAPK1 1908/4885SMN1; SMN2 808/4885 |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ESR1, ESR2, ESRRA | ALDH1A1 1672/4885MAPK1 2785/4885SMN1; SMN2 455/4885 |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | ALDH1A1 2214/4885MAPK1 1908/4885SMN1; SMN2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.